REBIF 132 MCG / 1.5 ML — DIN 02318261
INTERFERON BETA-1A : 132 MCG / 1.5 ML · EMD SERONO, A DIVISION OF EMD INC., CANADA · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is REBIF?
REBIF 132 MCG / 1.5 ML contains INTERFERON BETA-1A : 132 MCG / 1.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02318261, held by EMD SERONO, A DIVISION OF EMD INC., CANADA, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 14-May-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is REBIF used for?
REBIF (Interferon beta-1a Injection) is indicated for: The treatment of relapsing forms of multiple sclerosis (MS), to reduce the number and severity of clinical exacerbations, slow the progression of physical disability, reduce the requirement for steroids, reduce the number of hospitalizations for treatment of multiple sclerosis, and reduce T1 - Gd enhanced and T2 (burden of disease) lesions as seen on MRI. The treatment of patients who have experienced a single demyelinating event, accompanied by an active inflammatory process and an abnormal MRI scan with lesions typical of MS, who are determined to be at high risk of developing clinically definite multiple sclerosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Interferon Beta-1a in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Interferon Beta-1a, across 11 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| EMD SERONO, A DIVISION OF EMD INC., CANADA | 8 | 4 | REBIF | Sourceable in Canada |
| BIOGEN CANADA INC | 3 | 1 | AVONEX | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 132 MCG / 1.5 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | 22 mcg/0.5 mL and 44 mcg/0.5mL in pre-filled syringes supplied as 3-packs; 66 mcg/1.5 mL and 132 mcg/1.5 mL in pre-filled cartridges supplied as 4 pre-filled cartridges per box |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Interferon Beta-1a |
|---|---|
| ATC code | L03AB07 |
| AHFS class | 92:20.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02318261 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2318261 |
| Brand name | REBIF |
| Generic / active ingredient | INTERFERON BETA-1A : 132 MCG / 1.5 ML |
| Market authorization holder | EMD SERONO, A DIVISION OF EMD INC., CANADA |
| Health Canada schedule | Schedule D |
| ATC code | L03AB07 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L03AB |
| Current status | MARKETED |
| Status date | 14-May-2009 |
| Original market date | 2009-05-14 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 11 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AVONEX | 30 MCG / 0.5 ML | SOLUTION | BIOGEN CANADA INC | MARKETED | 02269201 |
| REBIF | 22 MCG / 0.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | MARKETED | 02237319 |
| REBIF | 44 MCG / 0.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | MARKETED | 02237320 |
| REBIF | 66 MCG / 1.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | MARKETED | 02318253 |
| AVONEX | 1.1 ML | POWDER FOR SOLUTION | BIOGEN CANADA INC | CANCELLED POST MARKET | 02237770 |
| AVONEX | 60 MCG | POWDER FOR SOLUTION | BIOGEN CANADA INC | APPROVED | 02267594 |
| REBIF | 132 MCG / 1.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED PRE MARKET | 02318288 |
| REBIF | 8.8 MCG / 0.2 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED POST MARKET | 02277492 |
| REBIF | 8.8 MCG / 0.2 ML | POWDER FOR SOLUTION ; KIT ; LIQUID | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED POST MARKET | 02281708 |
| REBIF | 2 ML | LIQUID ; KIT ; POWDER | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED POST MARKET | 02237317 |
2 · Same class — other molecules in ATC L03AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Interferon Beta-1a | AVONEX · REBIF | 11 | 5 | Yes |
| Peginterferon Beta-1a | PLEGRIDY | 4 | 2 | Yes |
| Interferon Beta-1b | BETASERON · EXTAVIA | 2 | 1 | Yes |
| Peginterferon Alfa-2a | PEGASYS | 2 | 1 | Yes |
| Peginterferon Alfa-2b, Combinations | PEGETRON · REBETRON READY TO USE SOLUTION (ALBUMIN(HUMAN)FREE) (6000000 IU/ML AND 200MG CAPSULES) · REBETRON SOLUTION (ALBUMIN (HUMAN) FREE) (18 MIU MULTI-DOSE PEN / 200MG CAPSULES) · VICTRELIS TRIPLE | 15 | 0 | Not in Canada |
| Interferon Alfa-2b | INTRON A · INTRON A - KIT (PWS+DILUENT) 3000000IU/VIAL · INTRON A - KIT (PWS+DILUENT) 5000000IU/VIAL · INTRON A - LIQ 5000000IU/ML · INTRON A INJ 10000000UNIT/VIAL · INTRON A INJ 3000000UNIT/VIAL · INTRON A INJ 5000000UNIT/VIAL | 13 | 0 | Not in Canada |
| Interferon Alfa-2a | ROFERON A SOLN INJ 6 MILLION · ROFERON A STERILE PWS 18M UNIT/VIAL · ROFERON A STERILE PWS 3M UNIT/VIAL · ROFERON A STERILE PWS 9M UNIT/VIAL · ROFERON-A SOL INJ 3MILLION IU/VIAL · ROFERON-A SOLN-LIQ IM SC 4.5MILLION I.U/ML · ROFERON-A SOLN-LIQ IM SC 9MILLION I.U./ML · ROFERON-A SOLUTION 18 MILLION I.U./3ML · ROFERON-A SOLUTION 3 MILLION I.U./ML · ROFERON-A SOLUTION 6 MILLION I.U./ML · ROFERON-A SOLUTION INJ 36000000UNIT/ML · ROFERON-A SOLUTION INJ. 9MILLION I.U./0.9ML | 12 | 0 | Not in Canada |
| Peginterferon Alfa-2b | UNITRON PEG | 4 | 0 | Not in Canada |
| Peginterferon Alfa-2a, Combinations | PEGASYS RBV | 2 | 0 | Not in Canada |
| Interferon Alfa-N1 | WELLFERON INJ 10 000 000UNIT/ML · WELLFERON INJ 3000000UNIT/ML | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L03AA | Ancestim · Filgrastim · Pegfilgrastim | 24 | 21 |
| L03AX | Bcg Vaccine · Glatiramer Acetate · Melanoma Vaccine · Plerixafor | 18 | 8 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.